Market Cap 6.37M
Revenue (ttm) 0.00
Net Income (ttm) -11.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,130,800
Avg Vol 9,176,024
Day's Range N/A - N/A
Shares Out 14.82M
Stochastic %K 5%
Beta 1.84
Analysts Strong Buy
Price Target $1.75

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology th...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 538 8200
Fax: 609 452 6467
Address:
29 Emmons Drive, Suite B-10, Princeton, United States
BmoreBoy89
BmoreBoy89 Jun. 15 at 9:40 PM
$SNGX https://theconversation.com/the-hunt-for-a-new-ebola-vaccine-two-scientists-explain-the-challenges-284452 Informative article from the scientists that recently received CEPI funding. Even the scientists have expressed the logistical challenges post vaccination development. This is where ThermoVax will be important and time is in the essence. Can anyone name a competitor that has a ebola Bundibugyo specific platoform that eliminates strict and expensive refrigeration?
0 · Reply
Ezflp1
Ezflp1 Jun. 15 at 2:04 AM
$SNGX https://www.tipranks.com/news/the-fly/barda-supporting-development-of-bundibugyo-ebolavirus-vaccine-candidates-thefly-news
0 · Reply
splendor
splendor Jun. 13 at 5:58 PM
$SNGX the timing makes perfect sense. On June 11th, the US State Department committed a massive $50M in funding to this exact CEPI call. When that kind of heavy government cash drops right before the buzzer, the agency is practically required to extend the deadline by a few days so applicants can adjust their budget proposals, scale up their planned trials, and meet the new funding criteria. This is great news for $SNGX for two reasons: Bigger Pie: There is now significantly more capital available to fund candidates. The "Fit": CEPI explicitly wants to fund multiple diverse approaches. With $50M more in the pot, Soligenix's heat-stable ThermoVax platform becomes an even more attractive, high-priority target for a slice of that budget, especially for deployment in infrastructure-heavy regions. It's not about lacking good submissions—it's about re-opening the door to account for a massive injection of US government money. Load up!
2 · Reply
BmoreBoy89
BmoreBoy89 Jun. 12 at 7:33 PM
$SNGX CEPI deadline extended to June 19th.
1 · Reply
Jmiz1986
Jmiz1986 Jun. 12 at 7:32 PM
$SNGX https://www.nytimes.com/2026/06/12/health/ebola-treatment-bundibugyo-virus.html Does anyone know if SnGx is one of the treatment they are testing ?
1 · Reply
AI_BULLBEAR
AI_BULLBEAR Jun. 12 at 6:34 PM
$SNGX Bullshit
1 · Reply
splendor
splendor Jun. 12 at 11:45 AM
$SNGX NAIROBI, June 12 (Reuters) - There are many “blind spots” in the Ebola outbreak in the Democratic Republic of Congo, a World Health Organization expert said on Friday, suggesting the spread of the deadly disease may be much wider than official estimates.
0 · Reply
FinacialSuicide
FinacialSuicide Jun. 12 at 8:26 AM
$SNGX If SNGX submits the grant application (the deadline is today), the company may issue a press release acknowledging submission. Hopefully we hear something today! 🤞
2 · Reply
Vote4Pedro2
Vote4Pedro2 Jun. 11 at 6:02 PM
0 · Reply
MondayFri
MondayFri Jun. 11 at 5:09 PM
$SNGX I understand that the grant applications are due tomorrow, June 12. Does anyone know how much money the govt is willing to hand out? Or how long it takes for the application process to complete? Thanks.
2 · Reply
Latest News on SNGX
Soligenix reports Q1 EPS (28c) vs. (97c) last year

2026-05-08T12:43:19.000Z - 5 weeks ago

Soligenix reports Q1 EPS (28c) vs. (97c) last year


Soligenix Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 5 weeks ago

Soligenix Quarterly report: Q1 2026


Soligenix Earnings release: Q1 2026

May 8, 2026, 7:00 AM EDT - 5 weeks ago

Soligenix Earnings release: Q1 2026


Soligenix Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 2 months ago

Soligenix Slides: Corporate presentation


Soligenix Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Soligenix Annual report: Q4 2025


Soligenix Slides: Corporate presentation

Mar 26, 2026, 7:00 AM EDT - 2 months ago

Soligenix Slides: Corporate presentation


Soligenix announces HyBryte clinical summary published

2026-03-19T11:36:43.000Z - 3 months ago

Soligenix announces HyBryte clinical summary published


Soligenix Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Soligenix Slides: Corporate presentation


Soligenix says SGX945 granted PIM designation in UK by MHRA

2026-03-10T11:42:32.000Z - 3 months ago

Soligenix says SGX945 granted PIM designation in UK by MHRA


Soligenix to Present at BIO Investment & Growth Summit

Feb 24, 2026, 7:30 AM EST - 3 months ago

Soligenix to Present at BIO Investment & Growth Summit


Soligenix Details Recent Progress and Upcoming Milestones

Feb 12, 2026, 7:30 AM EST - 4 months ago

Soligenix Details Recent Progress and Upcoming Milestones


Soligenix announces results from Phase 2a trial of SGX302

2025-12-17T12:36:34.000Z - 6 months ago

Soligenix announces results from Phase 2a trial of SGX302


Soligenix Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 7 months ago

Soligenix Quarterly report: Q3 2025


Soligenix expands European Medical Advisory Board for  CTCL

2025-09-30T11:35:29.000Z - 9 months ago

Soligenix expands European Medical Advisory Board for CTCL


Soligenix Announces Closing of $7.5 Million Public Offering

Sep 29, 2025, 4:05 PM EDT - 9 months ago

Soligenix Announces Closing of $7.5 Million Public Offering


Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 9 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering


Soligenix Registration statement: Registration Filing

Sep 19, 2025, 8:00 AM EDT - 9 months ago

Soligenix Registration statement: Registration Filing


Soligenix Slides: Corporate Presentation

Sep 19, 2025, 7:00 AM EDT - 9 months ago

Soligenix Slides: Corporate Presentation


Soligenix Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 10 months ago

Soligenix Quarterly report: Q2 2025


Soligenix receives FDA orphan designation for dusquetide

2025-08-13T22:00:32.000Z - 10 months ago

Soligenix receives FDA orphan designation for dusquetide


Soligenix Quarterly report: Q1 2025

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Quarterly report: Q1 2025


Soligenix Earnings release: Q1 2025

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Earnings release: Q1 2025


Soligenix Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing


Soligenix Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing


IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.


Soligenix Annual report: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Annual report: Q4 2024


Soligenix Earnings release: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Earnings release: Q4 2024


Soligenix to Present at BIO CEO & Investor Conference

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference


Soligenix to Present at Upcoming Investor Conferences

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences


Soligenix Quarterly report: Q3 2024

Nov 7, 2024, 7:00 PM EST - 1 year ago

Soligenix Quarterly report: Q3 2024


Soligenix Earnings release: Q3 2024

Nov 7, 2024, 7:00 PM EST - 1 year ago

Soligenix Earnings release: Q3 2024


BmoreBoy89
BmoreBoy89 Jun. 15 at 9:40 PM
$SNGX https://theconversation.com/the-hunt-for-a-new-ebola-vaccine-two-scientists-explain-the-challenges-284452 Informative article from the scientists that recently received CEPI funding. Even the scientists have expressed the logistical challenges post vaccination development. This is where ThermoVax will be important and time is in the essence. Can anyone name a competitor that has a ebola Bundibugyo specific platoform that eliminates strict and expensive refrigeration?
0 · Reply
Ezflp1
Ezflp1 Jun. 15 at 2:04 AM
$SNGX https://www.tipranks.com/news/the-fly/barda-supporting-development-of-bundibugyo-ebolavirus-vaccine-candidates-thefly-news
0 · Reply
splendor
splendor Jun. 13 at 5:58 PM
$SNGX the timing makes perfect sense. On June 11th, the US State Department committed a massive $50M in funding to this exact CEPI call. When that kind of heavy government cash drops right before the buzzer, the agency is practically required to extend the deadline by a few days so applicants can adjust their budget proposals, scale up their planned trials, and meet the new funding criteria. This is great news for $SNGX for two reasons: Bigger Pie: There is now significantly more capital available to fund candidates. The "Fit": CEPI explicitly wants to fund multiple diverse approaches. With $50M more in the pot, Soligenix's heat-stable ThermoVax platform becomes an even more attractive, high-priority target for a slice of that budget, especially for deployment in infrastructure-heavy regions. It's not about lacking good submissions—it's about re-opening the door to account for a massive injection of US government money. Load up!
2 · Reply
BmoreBoy89
BmoreBoy89 Jun. 12 at 7:33 PM
$SNGX CEPI deadline extended to June 19th.
1 · Reply
Jmiz1986
Jmiz1986 Jun. 12 at 7:32 PM
$SNGX https://www.nytimes.com/2026/06/12/health/ebola-treatment-bundibugyo-virus.html Does anyone know if SnGx is one of the treatment they are testing ?
1 · Reply
AI_BULLBEAR
AI_BULLBEAR Jun. 12 at 6:34 PM
$SNGX Bullshit
1 · Reply
splendor
splendor Jun. 12 at 11:45 AM
$SNGX NAIROBI, June 12 (Reuters) - There are many “blind spots” in the Ebola outbreak in the Democratic Republic of Congo, a World Health Organization expert said on Friday, suggesting the spread of the deadly disease may be much wider than official estimates.
0 · Reply
FinacialSuicide
FinacialSuicide Jun. 12 at 8:26 AM
$SNGX If SNGX submits the grant application (the deadline is today), the company may issue a press release acknowledging submission. Hopefully we hear something today! 🤞
2 · Reply
Vote4Pedro2
Vote4Pedro2 Jun. 11 at 6:02 PM
0 · Reply
MondayFri
MondayFri Jun. 11 at 5:09 PM
$SNGX I understand that the grant applications are due tomorrow, June 12. Does anyone know how much money the govt is willing to hand out? Or how long it takes for the application process to complete? Thanks.
2 · Reply
splendor
splendor Jun. 11 at 8:23 AM
$SNGX remember how $VXRT secured a massive $453M Project NextGen grant for their oral vaccine tablet? Why? Because global health agencies realized needles and extreme cold-chains don't work everywhere. ​Now look at Africa. WHO and Africa CDC just called for $68M+ to close Ebola/Bundibugyo research gaps. The biggest hurdle there? Absolute lack of cold-chain infrastructure. ​Enter Soligenix's ThermoVax® platform—100% heat-stable vaccines up to 40°C. They just applied for CEPI funding on June 8th. The institutional money is flowing directly toward heat-stable tech. ​Double-digit stock price is a matter of weeks to months as these massive grants hit. Load up before the PR drops!
1 · Reply
Biguled
Biguled Jun. 11 at 2:46 AM
0 · Reply
BmoreBoy89
BmoreBoy89 Jun. 11 at 1:07 AM
$SNGX If this product can execute, this stock could be the next Moderna. https://slate.com/news-and-politics/2026/06/ebola-outbreak-spreading-elon-musk-trump.html "In fact, this Ebola outbreak threatens to be the worst in history. Case numbers have shot up at an unprecedented rate. This species of Ebola, the Bundibugyo virus, is harder to detect, and there is no vaccine for it. It is hitting one of the most volatile regions of one of the world’s most fragile states. And it comes during a time of unprecedented retreat of the world’s most prosperous nations from the world’s most vulnerable—a move led by the United States and exemplified by the dismantling of the U.S. Agency for International Development last year."
0 · Reply
FinacialSuicide
FinacialSuicide Jun. 10 at 11:55 PM
$SNGX nice volume today! Hoping for a better day tomorrow!
0 · Reply
UWanSum
UWanSum Jun. 10 at 11:18 PM
$SNGX something is brewing here
0 · Reply
BmoreBoy89
BmoreBoy89 Jun. 10 at 8:54 PM
$SNGX https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026
0 · Reply
Axielg
Axielg Jun. 10 at 8:01 PM
$SNGX is this popping this AH?
0 · Reply
Tbt589
Tbt589 Jun. 10 at 6:22 AM
$SNGX if the application deadline is Friday, you guys think well get some news next week?
2 · Reply
BmoreBoy89
BmoreBoy89 Jun. 9 at 6:31 PM
$SNGX Are shorts holding this down?
0 · Reply
steppeh
steppeh Jun. 9 at 2:08 PM
$SNGX Let's go from the bottom! 🚀
0 · Reply
splendor
splendor Jun. 9 at 12:19 PM
$SNGX Congo says Ebola deaths top 100 as armed groups threaten response https://www.cnbcafrica.com/2026/congo-says-ebola-deaths-top-100-as-armed-groups-threaten-response
0 · Reply
splendor
splendor Jun. 9 at 11:38 AM
$SNGX Remember what $NVAX did after getting CEPI funding? Not saying it’s the exact same scenario, but don't underestimate how massive non-dilutive funding is for a micro-cap. Eyes on the June 12 deadline.
0 · Reply